



November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-005014-34/ Novartis Protocol ID CLGX818A2202

A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior chemotherapy

Trial CLGX818A2202 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.